Background {#Sec1}
==========

Elevated serum levels of C-reactive protein (CRP) are found in up to three quarters of patients with ischemic stroke \[[@CR8], [@CR26]\]. Increases in CRP may reflect a systemic inflammatory response following ischemic stroke, the extent of tissue injury, or concurrent infections. Moreover, in animal models of focal cerebral ischemia, CRP increased secondary brain damage through activation of the complement system \[[@CR13], [@CR22]\].

Several studies have assessed the value of CRP in the very early phase of stroke as a prognostic factor of functional outcome. These studies were either small, included a selected group of patients, or tested only the relation between CRP and mortality instead of functional outcome. The findings were inconclusive as some found a positive association \[[@CR6], [@CR18], [@CR20]\], but others not \[[@CR27], [@CR30]\].

Verification of the role of CRP as an early prognostic factor of functional outcome after ischemic stroke may be of clinical importance, because it is an easily-measured and readily available inflammatory marker. The aim of our study was therefore to determine the prognostic value of CRP measured in the very early phase of ischemic stroke for poor functional outcome and death in a large sample of patients with acute ischemic stroke.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

All patients included in the present study participated in the Paracetamol (Acetaminophen) In Stroke (PAIS) trial, a multicenter, randomized, placebo-controlled clinical trial of high-dose paracetamol in patients with acute stroke. The study protocol has been published earlier \[[@CR7], [@CR28]\]. In short, patients with ischemic stroke or intracerebral hemorrhage within 12 h of symptom onset with no history of liver disease or pre-stroke impairment (modified Rankin Scale (mRS) score \<2) \[[@CR29]\] were included in this study. Patients with ischemic stroke included in the PAIS trial between March 2003 and March 2007 in centers where CRP was measured as a part of routine laboratory assessment on admission were included in the present study if venous blood sampling for CRP was accomplished within 12 h of symptom onset.

Baseline variables {#Sec4}
------------------

Baseline clinical information was extracted from the trial records. This included body temperature on admission and 24 h later, stroke subtype according to the TOAST classification \[[@CR1]\], stroke severity as assessed with the NIH Stroke Scale (NIHSS) \[[@CR5]\], and cardiovascular risk factors. In addition, the occurrence of infections during hospitalization was assessed. Body temperature was measured with either tympanic or rectal thermometers.

Blood samples and CRP assay {#Sec5}
---------------------------

Blood samples for assessment of CRP and white blood cell count were taken on admission. The time of CRP measurement relative to stroke onset was recorded in all patients.

Levels of CRP were determined with a clinically validated assay. Participating centers used different analyzers (Dade Behring, Beckman LX-20, Beckman Synchron, Beckman Coulter DXC, Olympus 640, Ortho Vitros, Roche Cobas 6000, Roche Cobas Integra, Roche Hitachi 917, Roche Modular) to establish CRP levels. Intra- and inter-assay variation of all participating centers was evaluated by means of the external quality control scheme of the Dutch Foundation for Quality Assessment in Clinical Laboratories (SKML). If the intra-assay and/or inter-assay coefficient of variation was higher than 7.5%, patients from these centers were excluded from further analysis. All centers were subjected to quality review by the Dutch Foundation for Quality Assessment in Clinical Laboratories (SKML (<http://www.skml.nl>).

Some centers did not report exact values of CRP below a certain cut-off point, as values below these cut-off points were considered "normal" values. These cut-off points varied between 1 and 7 mg/L.

As extremely high levels of CRP likely reflect an infection at the time of blood sampling, patients in whom the level of CRP was higher than 2 SD above the mean were excluded from further analysis.

Outcome measures {#Sec6}
----------------

Poor outcome was defined as a score of more than 2 on the mRS, including death, at 3 months from stroke onset. A secondary outcome was death at 3 months. Outcome was assessed without knowledge of baseline CRP levels.

Statistical analysis {#Sec7}
--------------------

Statistical analyses were performed with Stata/SE 8.2 for Windows (Statacorp, College Station, Texas, USA). The relation between outcome and dichotomized CRP levels was expressed as an odds ratio (OR), with a corresponding 95% confidence interval (CI), through logistic regression.

CRP values were dichotomized at 7 mg/L. This cut-off point was selected, as this was the highest cut-off point below which values were considered normal and not reported as exact values by some centers. In order to study a possible level-risk relationship, all CRP values were recoded with 7 mg/L as the lower bound. Odds ratios were expressed per unit increase in logarithmically transformed CRP levels. Adjustments for the impacts of age, sex, baseline NIHSS score, cigarette smoking status, diabetes mellitus, hypertension, statin use, and stroke subtype (cardioembolic stroke versus non-cardioembolic stroke) was made with multiple logistic regression. We performed additional analyses to account for the potential confounding effect of antipyretic treatment by stratifying for treatment with acetaminophen.

Results {#Sec8}
=======

Between 1 March 2003 and 1 March 2007, 1187 patients were included in the PAIS trial. Sixteen of the 29 participating centers routinely performed CRP measurements on admission for acute stroke. In these 16 centers, 897 patients where included in the PAIS trial in the period under study. Of these patients, 336 were excluded from the present study because of hemorrhagic stroke (*n* = 117), CRP measurement not accomplished within 12 h of stroke onset or time of assessment unknown (*n* = 54), CRP measurements with analyzers with a variation coefficient \>7.5% (*n* = 56), or CRP levels over 110 mg/L (2 SD; *n* = 9).

The median CRP level was 5 mg/L (IQR 2--8) and 33% of patients had CRP levels of 7 mg/L or above.

Table [1](#Tab1){ref-type="table"} shows the baseline characteristics of the patients with CRP levels \<7 or ≥7 mg/L. Median time from onset of symptoms to CRP measurement was 137 min (range 0--696). Patients with CRP ≥7 mg/L were older, had higher scores on the NIHSS, had a slightly higher body temperature on admission, were more often smokers, more frequently had hypertension, diabetes mellitus, or atrial fibrillation, and less often used statins than patients with low CRP levels. Cardioembolic strokes were observed more often in patients with CRP ≥7 mg/L.Table 1Baseline characteristics of the study populationCRP \< 7 mg/LCRP ≥ 7 mg/L*p*Demographics *N*3771840.07 Age (years), mean (SD)69.1 (13.4)70.9 (13.8)0.98 Male226 (60%)110 (60%) Stroke severity^a^ NIHSS, mean (SD)7.5 (6.0)8.9 (6.6)0.02Risk factors Arterial hypertension183 (49%)107 (58%)0.03 Atrial fibrillation47 (12%)47 (26%)0.0005 Diabetes mellitus50 (13%)37 (20%)0.03 Current cigarette smoking108 (29%)70 (38%)0.03 Hypercholesterolemia104 (28%)42 (23%)0.30History Stroke84 (22%)40 (22%)0.68 Myocardial infarction47 (12%)25 (14%)0.92 Peripheral vascular disease25 (7%)21 (11%)0.09Physical examination Systolic blood pressure, mean (SD)169 (31)171 (34)0.63 Diastolic blood pressure, mean (SD)89 (18)89 (21)0.81 Body temperature, mean (SD)36.9 (0.6)37.0 (0.6)0.08Laboratory assessments Time until CRP measurement (min), median (range)140 (2--696)129 (0--681)0.64 Leukocytes 10^9^/L, mean (SD)8.2 (2.6)9.4 (3)0.0001Stroke type (TOAST)^b^ Undetermined189 (50%)81 (44%)0.09 Large vessel disease (≥50% stenosis)38 (10%)28 (15%)0.06 Cardiac source of embolism60 (16%)44 (24%)0.02 Small vessel occlusion49 (13%)24 (13%)0.88 Other determined etiology41 (11%)7 (4%)0.003Treatment RtPA95 (25%)50 (27%)0.42 Ace inhibitor65 (17%)38 (21%)0.46 Statin101 (27%)36 (20%)0.001^a^Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher values indicating more severe stroke \[[@CR5]\]^b^Based on the definitions of the Trial of ORG 10172 in Acute Stroke Therapy (TOAST) criteria \[[@CR1]\]

Sixteen patients with CRP ≥7 mg/L (9%) and 15 patients (4%) with CRP \<7 mg/L developed an infection during hospitalization. Two patients with CRP ≥7 mg/L had an infection (both pneumonia) within 24 h of stroke onset. No infections within 24 h were reported in patients with CRP \<7 mg/L.

No association between CRP levels and the body temperature at 24 h after study enrollment was found.

Patients with CRP levels ≥7 mg/L more often had a poor outcome (57 versus 42%; *p* = 0.006) or died (23 versus 13%; *p* = 0.0007) than patients with lower CRP levels (Fig. [1](#Fig1){ref-type="fig"}). Adjustment for potential confounders did not change these results (Table [2](#Tab2){ref-type="table"}).Fig. 1Association of CRP levels on admission with poor outcome or death at 3 monthsTable 2Association between increased CRP (≥7 mg/L) at baseline and outcome after ischemic strokeOR (95% CI)Adjusted OR (95% CI)^a^Poor outcome (mRS \> 2)1.9 (1.3--2.7)1.6 (1.1--2.4)Death2.0 (1.3--3.2)1.7 (1.0--2.9)^a^Adjusted for age, sex, NIHSS score, cigarette smoking, diabetes mellitus, hypertension, statin use, and stroke subtype

An additional stratified analysis to account for the potential confounding effect of treatment with acetaminophen did not affect the association.

A level-risk relationship was observed between CRP and poor outcome or death at 3 months. The relation between CRP and poor outcome was attenuated after adjustment for potential confounders (Table [3](#Tab3){ref-type="table"}).Table 3Level-risk relationship CRP and outcomeOR^a^ (95% CI)Adjusted OR^a,\ b^ (95% CI)Poor outcome (mRS \> 2)1.6 (1.2--2.2)1.3 (0.9--1.9)Death2.1 (1.5--3.0)1.9 (1.2--2.8)^a^ORs were expressed per 1 unit increase in logarithmically transformed CRP levels^b^Adjusted for age, sex, NIHSS score, cigarette smoking, diabetes mellitus, hypertension, statin use, and stroke subtype

After exclusion of patients who developed an infection during the first 2 weeks after stroke onset, the adjusted odds ratio for poor outcome was 1.5 (95% CI 1.0--2.3; *p* = 0.07), and for death 1.9 (95% CI 1.1--3.4).

Discussion {#Sec9}
==========

In this study, patients with CRP levels ≥7 mg/L within 12 h of ischemic stroke onset had a significantly increased risk of poor functional outcome or death at 3 months, even after adjustment for potential confounders. In addition, a level-risk relationship was found between CRP and poor outcome and death.

Several studies have found an association between increased CRP levels and clinical outcome in the time window between 12 and 72 h after ischemic stroke \[[@CR6], [@CR8], [@CR9], [@CR15], [@CR18], [@CR20], [@CR21], [@CR25]--[@CR27], [@CR30]\]. The results of previous studies that have aimed to assess the prognostic value of CRP in the very early phase of stroke are ambiguous. Two prospective studies did not observe a relation between CRP levels obtained within 6 or 12 h after symptom onset and death or dependency at follow-up \[[@CR27], [@CR30]\]. Both studies were rather small (127 and 111 patients) and may therefore have lacked the power to detect an association. In addition, one of these studies included only patients treated with rt-PA \[[@CR27]\].

In line with our results, three other studies found an association between CRP and outcome. In one of these studies, CRP was measured within 24 h of stroke onset, and 25% of the patients had a transient ischemic attack (TIA) instead of a stroke, which may have influenced the observed association \[[@CR6]\]. In addition, only the relation between CRP and mortality, and not disability, was studied. Other studies included only patients aged 75 years or older \[[@CR18]\], or patients who had a middle cerebral artery occlusion and received rt-PA \[[@CR20]\]. In the latter, an association with mortality was found, but functional outcome was not assessed \[[@CR20]\].

The strengths of the present study are its large sample size, robust outcome measures and early CRP measurement, which increase the relevance of our findings. Furthermore, detailed information on confounders was available.

Some methodological limitations should be discussed. First, this study was part of a larger clinical trial, and not designed to evaluate the prognostic value of CRP with regard to clinical outcome in acute ischemic stroke. As a consequence, a detailed history of inflammatory conditions was not recorded.

Levels were determined with different analyzers, which may have resulted in a systematic error. For this reason, measurements performed with analyzers with an inter-assay coefficient of variation ≥7.5% or that demonstrated bias relative to the other participating centers were excluded from further analysis. Secondly, the lowest detection limit for CRP varied from 1 to 7 mg/L among the centers. Therefore, CRP levels had to be dichotomized. This makes it more difficult to compare our results with previous studies. However, in three of the five studies that assessed the relation between CRP levels in the very early phase of acute stroke and clinical outcome, a similar cut-off point level was selected \[[@CR20], [@CR27], [@CR30]\]. Furthermore, all CRP values were recoded with 7 as the lower bound, in order to study a possible level-risk relationship.

A fourth issue might be that rather few patients with very severe stroke were included, which may affect the generalisability of the results.

In patients with ischemic stroke, increased levels of CRP may reflect a pre-existing degree of atherosclerosis or the presence of vascular risk factors. We found that patients with higher levels of CRP were more often smokers and more frequently had hypertension, diabetes mellitus, or atrial fibrillation. Furthermore, cardioembolic strokes were observed more often in patients with higher levels of CRP. Moreover, patients with CRP ≥7 mg/L used statins less often than patients with low CRP levels, suggesting that drugs in this class reduce levels of CRP. These findings are supported by previous studies \[[@CR2], [@CR10], [@CR17], [@CR18], [@CR23], [@CR24]\].

Why could CRP concentration be a prognostic factor for poor outcome and death? Early after onset of ischemic stroke, increased CRP levels may reflect an accompanying inflammatory reaction. Inflammatory processes play an important role in the pathophysiology of ischemic stroke \[[@CR19]\]. Cerebral ischemia triggers an inflammatory response characterized by activation and release of acute phase proteins such as C-reactive protein (CRP) and cytokines \[[@CR4], [@CR16], [@CR19]\]. The inflammatory processes may start within 2 h after stroke onset and sustain for days \[[@CR25]\], and may contribute to ischemic brain damage even in that early stage \[[@CR11]\].

Elevated CRP levels may be a reflection of the extent of brain injury. In our study, patients with CRP levels ≥7 mg/L had higher NIHSS scores on admission. Previous studies have shown that patients with increased CRP levels have larger infarctions \[[@CR25]\]. Although patients with CRP levels ≥7 mg/L taken as a group had worse outcomes at 3 months as assessed with the mRS, multiple logistic regression modeling indicated that the adverse outcome in this group remained even after adjustment for initial stroke severity by NIHSS score and multiple other risk factors for poor outcome. This suggests that CRP not only reflects the amount of tissue damage, but may also indicate a state of enhanced risk due to increased inflammation or cytokine excess. Interestingly, recent experimental studies have shown that CRP itself may contribute to secondary brain damage after focal cerebral ischemia, possibly via a complement-mediated exacerbation of tissue injury \[[@CR13], [@CR22]\]. In rats, treatment with human CRP after middle cerebral artery occlusion resulted in larger infarcts \[[@CR13]\]. Similar results have been observed in experimental models of myocardial infarction \[[@CR14]\].

It is therefore conceivable that increased levels of CRP following stroke are not only a consequence of brain infarction, but contribute to ischemic damage as well.

Increased CRP levels following ischemic stroke may also reflect concurrent infections. Secondary infections are common in the first week of stroke and are associated with poor outcome \[[@CR3], [@CR11], [@CR12]\], but they usually occur more than 12 h after stroke onset. In our study, only two clinically overt infections were reported within 24 h after stroke onset. In addition, we excluded patients in whom the CRP level exceeded 2 SD above the mean, who may have had an infection before stroke onset. Furthermore, exclusion of patients developing an early infection during hospitalization did not substantially affect the relation between CRP levels and poor functional outcome or death.

The use of biomarkers as predictors of stroke lesion evolution and prognosis is becoming increasingly important, as they may be valuable tools in the search for an optimal management of stroke patients. The present study confirms results from previous studies that have advocated CRP as a powerful prognostic marker in patients with ischemic stroke \[[@CR6], [@CR8], [@CR9], [@CR15], [@CR18], [@CR20], [@CR21], [@CR25], [@CR30]\]. It may provide important prognostic information beyond conventional clinical parameters. Further studies are needed to assess whether CRP is also a predictor of outcome after stroke.

Moreover, the fact that animal studies have found that CRP might exacerbate brain tissue damage following ischemic stroke, might stimulate research into the underlying pathogenetic mechanisms and development of new, more targeted, medical treatments for acute ischemic stroke.

Conclusion {#Sec10}
==========

Elevated CRP levels in the very early phase of acute ischemic stroke are independent prognostic factors for poor outcome at 3 months.
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